Microbial Gene Technology and Food Microbiology

The LMG group has a keen interest in bacteriocin research since late 80s to the present days, both fundamental and applied research. This includes bacteriocin screening, purification, functional genetics, quorum sensing/gene regulation, receptor identification and mode of action studies.

Our recent focus is to understand how bacteriocins interact with their receptors on target cells and how these interactions eventually lead to destruction of target cells. Knowledge from these studies is important to develop bacteriocins into safe and efficient applications, both as food preservatives and as novel drugs. We have  an increasing interest in applied research, especially to develop bacteriocins into drugs to fight antibiotic resistant pathogens. These activities are led by Prof. Dzung Diep

LMG has a longstanding research cooperation with the dairy company Tine on research on lactic acid bacteria.  This work is led by prof Helge Holo. Ongoing research activities include research on bacteriophages affecting dairy processes and strain and bacteriophage diversity in these processes. Moreover, we study vitamin K2 production in lactic acid bacteria and how that can be improved in dairy products.

We have some other subgroups in LMG: one working on microbial diversity (MicroDiv), led by Prof. Knut Rudi, and one (ACD Pharma) working on innovations in aquaculture.

The LMG group is led by Prof. Dzung Diep.

From basic research to applications
Foto
LMG


Relevant tools and competences

  • We have a high-through-put screening assay for bacteriocins targeting pathogens of interest
  • Our major pathogens of focus are MRSA, VRE and listeria
  • We have a well-established platform for bacteriocin studies covering both biochemical and genetic aspects.
  • We have established skin-infection models in mice for therapeutic studies.
  • We have diverse luciferase-tagged pathogens and an IVIS imaging camera for studying infection development in animal models.

 Recent/current research projects

  • 2016-2018: 2.5y-Research grant from Norwegian research council, program Biotek2021. Optimization project,. Developing bacteriocins into veterinary medicine. Role: PI; project# 254784;
  • 2017-2200: 3y-project. The bacteriocin enterocin K1 to fight vancomycin resistant enterococci (one PhD student for 3 years; financing source: NMBU). Role: PI
  • 2018-2021: 3y-project funded by RCN India-Norway program (BEDREHELSE). Use of bacteriocins to fight against secondary infections in connection with leprosy and diabetes. Role: PI; project# 273646;
  • 2018-2021: 3y-project funded by RCN programme FRIBIOMED. Enterococcal RseP as a target for new diagnostics and antibiotics. Role: PI; project# 275190
  • 2018-2021: 4y-EU-project-Ifermenter: iFERMENTER - CONVERSION OF FORESTRY SUGAR RESIDUAL STREAMS TO ANTIMICROBIAL PROTEINS BY INTELLIGENT FERMENTATION. Role: partner; Project# 790507
  • 2018-2021: 2y-Networking project-funded by RCN (HELSE-EU). iResist: Infeksjonsbiologi og antibiotikaresistens i et enhelse-perspektiv: fra epidemiologi til nye antibakterielle behandlingsstrategier. Coapplicant; project# 281884.
  • 2018-2021: 2y-Seed grant from Norwegian Centennial Chair Program (NOCC), a collaborative project between NMBU, UiO and UMN (USA), on antibiotic resistance. Role Co-PI
  • 2019-2021: 2y-Bacteriocins as alternatives to antibiotics for combating infections in veterinary Medicine, RCN program Forny. Role co-PI, Project# 296220

 

Group members (2019)

 

Published 3. juli 2014 - 12:33 - Updated 12. november 2019 - 18:34